Busulfan with fludarabine myeloablative conditioning regimen in myeloid neoplasms: A single center experience.

被引：0
|
作者：
Raj, Renju V.
Button, Anna M.
Dozeman, Lindsay
De Magalhaes-Silverman, Margarida
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e18000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18000
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Autografting for Hodgkin's disease (HD) using beam as conditioning regimen: A single-center experience.
    Gherlinzoni, F
    Magagnoli, M
    Zinzani, PL
    Mazza, P
    Ricci, P
    Motta, MR
    Rizzi, S
    Miggiano, MC
    Tura, S
    BONE MARROW TRANSPLANTATION, 1998, 21 : S167 - S167
  • [42] Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
    Hui Liu
    Xiao Zhai
    Zhaoyang Song
    Jing Sun
    Yang Xiao
    Danian Nie
    Yu Zhang
    Fen Huang
    Hongsheng Zhou
    Zhiping Fan
    Sanfang Tu
    Yonghua Li
    Xutao Guo
    Guopan Yu
    Qifa Liu
    Journal of Hematology & Oncology, 6
  • [43] A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies
    Yamamoto, Hisashi
    Uchida, Naoyuki
    Yuasa, Mitsuhiro
    Kageyama, Kosei
    Ota, Hikari
    Kaji, Daisuke
    Nishida, Aya
    Ishiwata, Kazuya
    Takagi, Shinsuke
    Tsuji, Masanori
    Asano-Mori, Yuki
    Yamamoto, Go
    Izutsu, Koji
    Masuoka, Kazuhiro
    Wake, Atsushi
    Yoneyama, Akiko
    Makino, Shigeyoshi
    Taniguchi, Shuichi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1844 - 1850
  • [44] TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
    Swoboda, R.
    Labopin, M.
    Giebel, S.
    Schroeder, T.
    Kroeger, N.
    Arat, M.
    Savani, B.
    Spyridonidis, A.
    Hamladji, R. M.
    Potter, V.
    Deconinck, E.
    Yakoub-Agha, I.
    Rambaldi, A.
    Ozdogu, H.
    Sanz, J.
    Nagler, A.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 35 - 35
  • [45] Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children
    Harris, Andrew C.
    Boelens, Jaap Jan
    Ahn, Kwang Woo
    Fei, Mingwei
    Abraham, Allistair
    Artz, Andrew
    Dvorak, Christopher C.
    Frangoul, Haydar
    Freytes, Cesar O.
    Gale, Robert Peter
    Hong, Sanghee
    Lazarus, Hillard M.
    Mineishi, Shin
    Nishihori, Taiga
    O'Brien, Tracey
    Williams, Kirsten M.
    Pasquini, Marcelo C.
    Levine, John E.
    BLOOD, 2016, 128 (22)
  • [46] Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis
    Shuhei Kurosawa
    Yoshimitsu Shimomura
    Hidehiro Itonaga
    Yuho Najima
    Takeshi Kobayashi
    Yukiyasu Ozawa
    Yoshinobu Kanda
    Shinichi Kako
    Toshiro Kawakita
    Ken-ichi Matsuoka
    Yumiko Maruyama
    Shuichi Ota
    Hideyuki Nakazawa
    Kazunori Imada
    Junya Kanda
    Takahiro Fukuda
    Yoshiko Atsuta
    Jun Aoki
    Bone Marrow Transplantation, 2021, 56 : 3008 - 3015
  • [47] Fludarabine and oral busulfan: a low toxicity conditioning regimen when plasma level targeting and intravenous busulfan is not available. A Brazilian experience
    Simoes, B
    Souza, MP
    Mauad, M
    Machado, C
    Paton, EJ
    Pieroni, F
    Colli, G
    Zaparolli, Y
    Stracieri, AB
    Oliveira, MC
    Moraes, D
    Voltarelli, JC
    Colturato, VR
    BONE MARROW TRANSPLANTATION, 2006, 37 : S115 - S115
  • [48] Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis
    Kurosawa, Shuhei
    Shimomura, Yoshimitsu
    Itonaga, Hidehiro
    Najima, Yuho
    Kobayashi, Takeshi
    Ozawa, Yukiyasu
    Kanda, Yoshinobu
    Kako, Shinichi
    Kawakita, Toshiro
    Matsuoka, Ken-ichi
    Maruyama, Yumiko
    Ota, Shuichi
    Nakazawa, Hideyuki
    Imada, Kazunori
    Kanda, Junya
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Aoki, Jun
    BONE MARROW TRANSPLANTATION, 2021, 56 (12) : 3008 - 3015
  • [49] Busulfan and fludarabine is a safe and effective conditioning regimen for allogenic sibling bone marrow transplantation in adults with acute myeloid leukemia
    Fagot, T.
    Konopacki, J.
    Malfuson, J.
    Janus, G.
    Souleau, B.
    De Revel, T.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (09) : 72 - 73
  • [50] Busulfan-Based Intensified Myeloablative Conditioning Regimen Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia-Single Center Study
    Wang, Yun
    Sun, Ruijuan
    Zhao, Yanli
    Wei, Zhijie
    Xiong, Min
    Liu, Deyan
    Lu, Peihua
    Lu, Yue
    BLOOD, 2024, 144 : 7328 - 7328
12345